U.S. FDA Renews DILIsym® Software Licenses for 7th Year
- None.
- None.
Insights
The renewal of the FDA's license for DILIsym software underscores the growing emphasis on quantitative systems toxicology (QST) in drug development and regulatory evaluation. The ability to predict drug-induced liver injury (DILI) is a significant concern for pharmaceutical companies, as liver toxicity can lead to serious adverse events, potentially halting drug development and causing financial losses. The use of DILIsym by the FDA indicates a proactive approach to safety evaluation, which could result in a more streamlined approval process for drugs with a favorable DILI profile. Pharmaceutical companies may consider investing in similar technologies or participating in the DILI-sim Initiative to stay aligned with regulatory trends and mitigate the risk of late-stage drug development failures.
The partnership between Simulations Plus and the FDA via the DILI-sim Initiative represents a strategic alignment with long-term implications for the healthcare industry. The adoption of advanced simulation platforms like DILIsym by regulatory agencies suggests an industry shift towards precision in safety assessments. From an investor's perspective, companies that are members of the DILI-sim Initiative or possess commercial licenses for DILIsym may have a competitive advantage. This could translate into enhanced drug pipelines and potentially higher success rates in drug approvals, positively impacting stock valuations. Moreover, the continued collaboration between public and private entities in developing such platforms could signal future opportunities for growth and innovation in this space.
The announcement by Simulations Plus not only highlights the importance of DILIsym in the regulatory review process but also demonstrates the company's ongoing commitment to innovation and partnership with the FDA. As a market research analyst, one would assess the broader market implications, noting that the demand for predictive modeling tools is likely to increase as the pharmaceutical industry continues to seek efficient ways to navigate the complex regulatory environment. The software's ability to predict DILI risk and tailor dosing strategies enhances its value proposition. For stakeholders, the implications are twofold: there's the potential for Simulations Plus to secure additional commercial licenses and for pharmaceutical companies to reduce R&D costs and time-to-market for new drugs, potentially leading to favorable market movements for those invested in the sector.
Predicting DILI risk supports informed decision-making regarding drug evaluations and approvals
DILIsym predicts the potential for DILI risk in new molecules and provides deeper insight into the mechanisms responsible for observed DILI responses at various stages of the development process. This allows pharmaceutical development teams to understand their compounds and tailor proposed dosing strategies for efficacy and safety. It also allows the FDA to evaluate the potential DILI risk across multiple populations, which supports informed decision-making regarding drug approvals.
Dr. Paul B. Watkins, chair of the Scientific Advisory Board of the DILI-sim Initiative, said, “It is now known what properties to avoid to minimize liver toxicity in a new drug candidate -- but these same properties are often necessary to have therapeutic efficacy. By predicting safe dosing regimens of such drugs, DILIsym is now enabling successful development of important therapies that might otherwise be abandoned.”
“By incorporating disease pathophysiology, clinical presentation, and clinical outcomes into a unified framework, quantitative systems pharmacology (QSP) and toxicology (QST) models are powerful tools for evaluating therapies,” said Dr. Brett A. Howell, President of Quantitative Systems Pharmacology Solutions at Simulations Plus. “It’s exciting to see the FDA incorporate these methodologies and our software platform as part of their review process for submissions.”
For the last 14 years, Simulations Plus has coordinated the DILI-sim Initiative, which is a public-private partnership that guides the development of the DILIsym platform. DILIsym is available to the pharmaceutical and chemical industries for direct use to predict and understand liabilities via membership in the DILI-sim Initiative consortium and/or commercial licenses. Simulations Plus also routinely uses DILIsym for comprehensive consulting services on safety-related issues. Companies interested in a free trial version of the DILIsym software can request it here.
About Simulations Plus, Inc.
Serving clients worldwide for more than 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions. We offer solutions that bridge artificial intelligence (AI)/machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on LinkedIn | X | YouTube.
Environmental, Social, and Governance (ESG)
We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2023 ESG update.
Forward-Looking Statements
With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports and filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240404385811/en/
Simulations Plus Investor Relations
Renee Bouche
661-723-7723
renee.bouche@simulations-plus.com
Financial Profiles
Lisa Fortuna
310-622-8251
slp@finprofiles.com
Source: Simulations Plus, Inc.
FAQ
What does Simulations Plus, Inc. (SLP) announce regarding the FDA licenses?
What is the significance of DILIsym software in predicting drug-induced liver injury risk?
Who highlighted the importance of predicting safe dosing regimens for effective therapies?
What methodology is being incorporated by the FDA for submissions review?
How long has Simulations Plus coordinated the DILI-sim Initiative?
